Quick Answer
OnKure Therapeutics, Inc. reported Diluted EPS of $4.40 per share (loss) for fiscal year 2025.
OnKure Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$4.40 | +71.2% |
| 2024 | -$15.28 | +87.7% |
| 2023 | -$124.41 | -5768.4% |
| 2022 | -$2.12 | +3.2% |
| 2021 | -$2.19 | +77.2% |
| 2020 | -$9.60 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.09 | +97.0% | +4.4% |
| June 30, 2025 | -$1.14 | +97.5% | +4.2% |
| March 31, 2025 | -$1.19 | +96.1% | +96.7% |
| September 30, 2024 | -$36.55 | -543.5% | +18.5% |
| June 30, 2024 | -$44.82 | -6795.4% | -47.6% |
| March 31, 2024 | -$30.37 | -4961.7% | -434.7% |
| September 30, 2023 | -$5.68 | -971.7% | -773.8% |
| June 30, 2023 | -$0.65 | -30.0% | -8.3% |
- OnKure Therapeutics, Inc. showed an increase of +71.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, OnKure Therapeutics, Inc.’s diluted eps has grown by 54.2% (from $9.60 per share (loss) to $4.40 per share (loss)).
- The most recent figure is from OnKure Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: